Hong-yi Zhao

Shaanxi 710061, PR China
Puerto Rico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.

Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.

Journal: Bioorganic & medicinal chemistry

Published: August 19, 2025

Lysine-Targeted Covalent Strategy Leading to the Discovery of Novel Potent PROTAC-Based PI3Kδ Degraders.

Lysine-Targeted Covalent Strategy Leading to the Discovery of Novel Potent PROTAC-Based PI3Kδ Degraders.

Journal: Journal of medicinal chemistry

Published: May 31, 2025

EGFR tyrosine kinase inhibitor ZZC4 overcomes acquired resistance to gefitinib.

EGFR tyrosine kinase inhibitor ZZC4 overcomes acquired resistance to gefitinib.

Journal: Toxicology and applied pharmacology

Published: December 02, 2024

Lysine-Targeted Covalent Inhibitors of PI3Kδ Synthesis and Screening by In Situ Interaction Upgradation.

Lysine-Targeted Covalent Inhibitors of PI3Kδ Synthesis and Screening by In Situ Interaction Upgradation.

Journal: Journal of medicinal chemistry

Published: November 19, 2024

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.

Journal: European journal of medicinal chemistry

Published: August 29, 2023

Anticancer effect of covalent purine-containing EGFR TKI, ZZC4 and its mechanism of action through network pharmacology.

Anticancer effect of covalent purine-containing EGFR TKI, ZZC4 and its mechanism of action through network pharmacology.

Journal: Life sciences

Published: July 22, 2023

Design, synthesis and evaluation of new pyrimidine derivatives as EGFRC797S tyrosine kinase inhibitors.

Design, synthesis and evaluation of new pyrimidine derivatives as EGFRC797S tyrosine kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 06, 2023

Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups.

Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups.

Journal: Journal of medicinal chemistry

Published: September 29, 2022

Progress of small molecules for targeted protein degradation: PROTACs and other technologies.

Progress of small molecules for targeted protein degradation: PROTACs and other technologies.

Journal: Drug development research

Published: September 11, 2022

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.

Journal: Bioorganic chemistry

Published: April 22, 2022

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.

Journal: Journal of medicinal chemistry

Published: March 07, 2022

Identification of benzamides derivatives of norfloxacin as promising microRNA-21 inhibitors via repressing its transcription.

Identification of benzamides derivatives of norfloxacin as promising microRNA-21 inhibitors via repressing its transcription.

Journal: Bioorganic & medicinal chemistry

Published: January 11, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026